<DOC>
	<DOCNO>NCT02246998</DOCNO>
	<brief_summary>This study ass glomerular function administration stribild ( STB ; elvitegravir [ EVG ] /cobicistat [ COBI ] /emtricitabine [ FTC ] /tenofovir DF [ TDF ] ) regimen contain TDF without COBI ritonavir-boosted atazanavir ( ATV/r ) plus truvada ( TVD ; FTC/TDF ) atripla ( ATR ; efavirenz [ EFV ] /FTC/TDF ) compare regimen contain neither TDF COBI ATV/r plus abacavir/lamivudine ( ABC/3TC ) via determination actual glomerular filtration rate ( aGFR ) use iohexol ( probe GFR marker ) plasma clearance estimate ( calculate ) glomerular filtration rate ( eGFR ) . This study ass tubular function administration stribild , ATV/r plus TVD , atripla compare regimen ATV/r plus ABC/3TC . This study also evaluate pharmacokinetics ( PK ) , antiviral activity , efficacy , safety , tolerability three treatment regimens 24 week treatment .</brief_summary>
	<brief_title>Renal Effect Stribild Other Tenofovir DF-containing Regimens Compared Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine Antiretroviral Treatment-naive HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Treatment naïve Plasma HIV1 RNA level ≥ 5,000 copies/mL Screening CD4 cell count &gt; 200 cells/µL Screening genotype report provide site must show sensitivity FTC , TDF , EFV , ABC , 3TC , ATV absence study drug resistance mutation include K65R , K70E M184V RT Estimated GFR ≥ 70 mL/min Hepatic transaminase ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL ( ≤ 26 umol/L ) , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm^3 ; platelet ≥ 50,000/mm^3 ; hemoglobin ≥ 8.5 g/dL ) Serum amylase ≤ 5 × ULN ( individual serum amylase &gt; 5 × ULN remain eligible serum lipase ≤ 5 × ULN ) Normal electrocardiogram ( ECG ) clinically significant abnormal ECG Not pregnant nonlactating female nonchildbearing potential . Or female childbearing potential agree utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 90 day take EFV/FTC/TDF 30 day study drug follow last study drug dose Males agree utilize highly effective method contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence first dose throughout study period 90 day take EFV/FTC/TDF 30 day study drug follow last study drug dose . Males agree refrain sperm donation first dose least 90 day take EFV/FTC/TDF 30 day study drug follow last study drug dose Body mass index ( BMI ) 19 ≤ BMI ≤ 30 kg/m^2 body weight ≥ 40 kg Life expectancy ≥ 1 year HLAB*5701 allele positive A new AIDSdefining condition diagnose within 30 day prior screen Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C virus ( HCV ) antibody positive HCV RNA detectable Individuals experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test Have implant defibrillator pacemaker Current alcohol substance could potentially interfere study compliance A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Individuals cutaneous KS eligible , must receive systemic therapy KS within 30 day Day 1 Visit must anticipate require systemic therapy study Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Day 1 Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>